slide-01 slide-02 Screen4

Technology Platform

image-01

VaxInnate's Technology Platform is revolutionizing how vaccines are created and produced.

Explore

Product Pipeline

image-02

Learn more about our vaccines currently in our development pipeline

View

In The News

VAX2012Q-90

08 Dec 2014 - VaxInnate Initiates Phase 1b/2 Clinical Trial of Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, in Elderly

- Study to assess safety and immunogenicity in high-priority, at-risk population; top-line results expected in second quarter of 2015 – CRANBURY, NJ, December 8, 2014 – VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology platform, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 1b/2 study of VAX2012Q in healthy adults 65-75 […]

Read